Zusammenfassung
Sutherlandia frutescens (L.) R.Br., der Krebsbusch (Fabaceae), ist seit langem in der traditionellen Medizin des südlichen Afrikas bekannt als Arzneipflanze zur Behandlung eines breiten Spektrums von Krankheiten, das von der Anwendung bei bestimmten Krebsarten, Virusinfektionen, Diabetes, zentralnervösen und gastrointestinalen Störungen bis hin zu Entzündungen und rheumatischen Erkrankungen reicht. In jüngster Zeit konnten mit Hilfe moderner wissenschaftlicher Methoden antioxidative, antiinflammatorische, hypoglykämische, antivirale und antiproliferative Effekte in vitro, teilweise auch in tierexperimentellen Studien nachgewiesen werden. Als Inhaltsstoffe wurden bisher u.a Aminosäuren, Zucker, Phenole, Sterole und ein Triterpensaponin identifiziert. Die Toxizität der nicht proteinogenen Aminosäure L-Canavanin, die häufiger aus Samen von Fabaceen der Unterfamilie Faboideae (syn. Papilionoideae) isoliert wurde, ist gut dokumentiert, jedoch sind in tierexperimentellen Studien bisher keine Hinweise auf toxische Effekte des Gesamtextraktes von S. frutescens registriert worden.
Summary
Sutherlandia frutescens (L.) R.Br., the cancer bush from the Fabaceae family, has been known in traditional medicine of southern Africa for a long time as a multipurpose medicinal plant for curing certain types of cancers, viral infections, diabetes, central nervous and gastrointestinal disorders, inflammations as well as rheumatic diseases. Recently, modern scientific methods have confirmed antioxidative, anti-inflammatory, hypoglycaemic, antiviral and anti-proliferative effects in vitro, partly also in animal models. Amino acids, sugars, phenols, sterols and a triterpensaponine have hitherto been identified as the ingredients. Despite the well documented toxicity of L-canavanine, a non-proteinogenic amino acid often found in seeds of members of the Fabaceae, subfamily Faboideae (syn. Papilionoideae), no toxic effects have been observed for the Sutherlandia frutescens-extract in animal models so far.
Schlüsselwörter
Sutherlandia frutescens - Lessertia - Fabaceae - traditionelle Medizin - Südafrika - antioxidativ - antiinflammatorisch - hypoglykämisch - antiproliferativ - L-Canavanin
Key words
Sutherlandia frutescens - Lessertia - Fabaceae - traditional medicine - Africa - antioxidative - anti-inflammatory - hypoglycaemic - anti-proliferative - L-canavanine
Literatur
-
1
Bailey CJ, Day C.
Traditional plant medicines as treatments for diabetes.
Diabetes Care.
1989;
12
553-564
-
2
Bell EA, Lackey JA, Polhill RM.
Systematic significance of canavanine in the Papilionoideae (Faboideae).
Biochem Syst Ecol.
1978;
6
210-212
-
3
Bence AK, Worthen DR, Adams VR, Crooks PA.
The antiproliferative effects of L-canavanine and L-canaline.
Anticancer Drugs.
2002;
13
313-320
-
4
Bence AK, Crooks PA.
The mechanism of L-canavanine cytotoxicity: arginyl tRNA synthetase as a novel target for anticancer drug discovery.
J Enzyme Inhib Med Chem.
2003;
18
383-394
-
5
Chinkwo KA.
Sutherlandia frutescens extracts can induce apoptosis in cultured carcinoma cells.
J Ethnopharmacol.
2005;
98
163-170
-
6
Curtis W.
The botanical magazine: Colutea frutescens. Scarlett bladder-senna.
London: Couchman.
1792;
6
-
7
Ding Y, Matsukawa Y, Ohtani-Fujita N. et al. .
Growth inhibition of A549 human lung adenocarcinoma cells by L-canavanine is associated with p21/WAF1 induction.
Jpn J Cancer Res.
1999;
90
69-74
-
8
Fernandes AC, Cromarty AD, Albrecht C, Jansen van Rensburg CE.
The antioxidant potential of Sutherlandia frutescens.
J Ethnopharmacol.
2004;
95
1-5
-
9
Goldblatt P, Manning JC.
Cape plants. A conspectus of the Cape Flora of South Africa.
Strelitzia.
2000;
9
708
-
10
Hamburger M, Hostettmann K.
Bioactivity in plants: the link between phytochemistry and medicine.
Phytochemistry.
1991;
30
3864-3874
-
11
Harnett SM, Oosthuizen V, van de Venter M.
Anti-HIV activities of organic and aqueous extracts of Sutherlandia frutescens and Lobostemon trigonus.
J Ethnopharmacol.
2005;
96
113-119
-
12
Jang MH, Jun DY, Rue SW, Han KH, Park W, Kim YH.
Arginine antimetabolite L-canavanine induces apoptotic cell death in human Jurkat T cells via caspase-3 activation regulated by Bcl-2 or Bcl-xL.
Biochem Biophys Res Com.
2002;
295
283-288
-
13 Jaume JH Saint-Hillaire. Traité des arbrisseaux et des arbustes cultivés en France et en plein. Paris: Eigenverlag 1825
-
14
Katerere DRP, Eloff JN.
Antibacterial and antioxidant activity of Sutherlandia frutescens.
South African J Bot.
2003;
69
234
-
15 Kim Y, Gruen RS, MacDonald RS, Fernando LN. Antioxidative activities of Sutherlandia frutescens (subs. microphylla) extract. Abstract. Annual Congress of the Institute of Food Technologists, The Society for Food Science and Technology, Las Vegas 2004
-
16
Kundu JK, Mossanda KS, Na HK, Surh YJ.
Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens DC. on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets.
Cancer Lett.
2005;
218
21-31
-
17
Li X, Atkinson RN, King SB.
Preparation and evaluation of new L-canavanine derivatives as nitric oxide synthase inhibitors.
Tetrahedron.
2001;
47
6557-6565
-
18
Mills E, Foster BC, Heeswijk RV. et al. .
Impact of African herbal medicines on antiretroviral metabolism.
AIDS.
2005;
19
95-97
-
19
Morimoto I, Shiozawa S, Tanaka Y, Fujita T.
L-Canavanine acts on suppressor-inducer T cells to regulate antibody synthesis: Lymphocytes of systemic lupus erythematosus patients are specifically unresponsive to L-canavanine.
Clin Immun Immunpath.
1990;
55
97-108
-
20
Moshe D, van der Bank H, van der Bank M, van Wyk BE.
Lack of genetic differentiation between 19 populations from seven taxa of Sutherlandia tribe: Galegeae, Fabaceae.
Biochem Syst Ecol.
1998;
26
595-609
-
21 N. N.. Sutherlandia Frutescens Herba. Monographie. Last updated: 29-Apr-2004. www.sahealthinfo.org/traditionalmeds/monographs/sutherlandia.htm
-
22 N. N.. Sutherlandia frutescens. Monographie. Stand 4.11.2005. www.sutherlandia.com
-
23 N. N.. Sutherlandia frutescens. Monographie. Stand 4.11.2005. www.sutherlandia.org
-
24 N. N.. Agribusiness in sustainable natural African plant products (A-SNAPP). Stand: April 2000. www.cnrs.fr/DRI/Pretoria/Actualite/Notes/Agribusiness.htm
-
25
N. N..
Pharmaceuticals from plants: great potential, few funds [Editorial].
Lancet.
1994;
343
1513-1515
-
26
Na HK, Mossanda KS, Lee JY, Surh YJ.
Inhibition of phorbol ester-induced COX-2 expression by some edible African plants.
BioFactors.
2004;
21
149-153
-
27
Neuwinger HD.
Pflanzen zur Behandlung von Diabetes mellitus in der afrikanischen traditionellen Medizin - eine Übersicht.
Z Phytotherapie.
2004;
25
224-233
-
28
Ojewole JA.
Analgesic, antiinflammatory and hypoglycemic effects of Sutherlandia frutescens R. BR. (variety incana E. MEY.) [Fabaceae] shoot aqueous extract.
Methods Find Exp Clin Pharmacol.
2004;
26
409-416
-
29
Phillips EP, Dyer RA.
The genus Sutherlandia R.
Br. Rev SudAmer Bot.
1934;
1
69-80
-
30
Platel K, Srinivasan K.
Plant foods in the management of Diabetes mellitus: vegetables as potential hypoglycaemic agents.
Nahrung.
1997;
41
68-74
-
31
Prevoo D, Smith C, Swart P, Swart AC.
The effect of Sutherlandia frutescens on steroidogenesis: confirming indigenous wisdom.
Endocrine Res.
2004;
30
745-751
-
32
Rosenthal GA.
Metabolism of L-canavanine and L-canaline in leguminous plants.
Plant Physiol.
1990;
94
1-3
-
33
Rosenthal GA.
The biochemical basis for the deleterious effects of L-canavanine.
Phytochemistry.
1991;
30
1055-1058
-
34
Rosenthal GA.
L-Canaline: a potent antimetabolite and anti-cancer agent from leguminous plants.
Life Science.
1997;
60
1635-1641
-
35
Schrire BD, Andrew S.
Sutherlandia: gansies or balloon peas: part 1.
The Plantsman.
1992;
14
65-69
-
36 Seier J, Mdhluli M, Dhansay MA. et al. .A toxicity study of Sutherlandia leaf powder (Sutherlandia microphylla) consumption. Final report April 2002. Studie mit Unterstützung des Medical Research Council of South Africa und der National Research Foundation. www.sahealthinfo.org/traditionalmeds/firststudy/htm
-
37
Sia C.
Spotlight on ethnomedicine: Usability of Sutherlandia frutescens in the treatment of diabetes.
Rev Diab Stud.
2004;
1
145-149
-
38
Swaffar DS, Ang CY.
Growth inhibitory effect of L-canavanine against MIA PaCa.2 pancreatic cancer cells is not due to conversion to its toxic metabolite canaline.
Anticancer Drugs.
1999;
10
113-118
-
39
Tai J, Cheung S, Chan E, Hasman D.
In vitro culture studies of Sutherlandia frutescens on human tumor cell lines.
J Ethnopharmacol.
2004;
93
9-19
-
40
Thomas DA, Rosenthal GA, Gold DV, Dickey K.
Growth inhibition of a rat colon tumor by L-canavanine.
Cancer Res.
1986;
46
2898-2903
-
41 Thomson S. Canavanine toxicity: is Sutherlandia a healthy herb or potent(ial) poison? HIV positives and AIDS sufferers beware: the remedy may be worse than the alleged disease. Gaia Research Institute. www.gaiaresearch.co.za/sutherlandia.html
2002
-
42 Thomson S. Sutherlandia »fails« safety test. Gaia Research Institute. www.gaiaresearch.co.za/sutherlandia.html
2002
-
43
Turner BL, Harborne JB.
Distribution of canavanine in the plant kingdom.
Phytochemistry.
1967;
6
863-866
-
44 van Wyk BE, van Oudtshoorn B, Gericke N. Medicinal Plants of South Africa. Pretoria: Briza Publications 1997: 246-247
-
45 Watt C, Breyer-Brandwijk MG. The Medicinal and Poisonous Plants of Southern and Eastern Africa. Edinburgh, London: Livingstone 1962: 649
-
46 Xaba PMA, Notten A. Sutherlandia frutescens (L.) R. Br. Monographie vom April 2003. www.plantzafrica.com/plantqrs/sutherfrut.htm
2003
Dr. Klaus Peter Latté
Apotheker
Warägerweg 21
13595 Berlin
eMail: klauspeter.latte@lycos.de
